Modification Tadalafil and Macitentan tablets to aerosol

Paul Zarogoulidis,Dimitris Petridis,Chrysa Sardeli,Christoforos Kosmidis,Kosmas Tsakiridis,Dimitris Matthaios,Haidong Huang,Chong Bai,Wolfgang Hohenforst-Schmidt,Georgia Pitsiou,Ioannis Kioumis,George Giannakoulas,Savas Petanidis,Chrysanthi Karapantzou
DOI: https://doi.org/10.31083/j.fbl2701019
2022-01-13
Abstract:Introduction: Aerosolised drugs have been approved for several diseases such as cystic fibrosis and diabetes. Moreover; there are already drugs for pulmonary hypertension in aerosol form already on the market. Materials and methods: Two drugs for pulmonary hypertension (Tadalafil and Macitentan) were milled and transformed from tablets to powder. Three different jet-nebulizers with seven different residual cups were combined. Moreover, we used 3 different ultrasound nebulizers with two different release methods. Results: The drug and residual cup designs produce alone or jointly different MMAD diameters. The three large (10 mls) residual cups with the jet-nebulisers produced the smallest aerosol droplets. Both ultrasound nebulisers are capable of producing optimal size aerosol droplets ≤5 μm mmad. Conclusions: These two drugs can be easily administered as aerosol and an vivo clinical study will prove the safety for the airways.
What problem does this paper attempt to address?